Darrell J. Yamashiro, MD, PhD
Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation
Darrell J. Yamashiro, MD, PhD is a pediatric oncologist who specializes in the care of children with pediatric solid tumors, especially neuroblastoma, Wilms' tumor and other kidney tumors, and liver tumors such hepatoblastoma and hepatocellular carcinoma.
Although liver tumors in children are rare (they account for only one to two percent of childhood cancers), they can be very complex and require a multidisciplinary approach for optimal management. Dr. Yamashiro enjoys working as part of a team of physicians, nurse practitioners, nurses, social workers, child life specialists, and other dedicated healthcare professionals who deeply care about patients and who provide care with compassion and comfort.
Dr. Yamashiro also conducts basic science research. The latest advances in tumor genetics and the design of innovative therapies make this a very exciting time. For example, he and his team have done extensive research on the genetics of hepatoblastoma and developed mouse models, entering the phase of research where they are taking a personalized/precision medicine approach to this disease. They are also identifying novel genes that specifically target neuroblastoma-information that may be used to create targeted therapies.
- Cancer Care
- Pediatric Liver Cancer
- Wilm's Tumor
- Pediatric Solid Tumors
Banerjee D, Hernandez SL, Garcia A, Kangsamaksin T, Sbiroli E, Andrews J, Forrester LA, Wei N, Kadenhe-Chiweshe A, Shawber CJ, Kitajewski JK, **Kandel JJ, **Yamashiro DJ. Notch suppresses angiogenesis and progression of hepatic metastases. Cancer Res. 2015;75(8):1592-1602. PMID: 25744722; PMCID: PMCPMC4401639.
Glade Bender J, Blaney SM, Borinstein S, Reid JM, Baruchel S, Ahern C, Ingle AM, Yamashiro DJ, Chen A, Weigel B, Adamson PC, Park JR. A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report. Clin Cancer Res. 2012;18(18):5081-5089. PMID: 22791883; PMCID: PMC3445751.
Glade Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, Kerbel RS, Cooney-Qualter EM, Stempak D, Chen HX, Nelson MD, Krailo MD, Ingle AM, Blaney SM, Kandel JJ, Yamashiro DJ, Children's Oncology Group S. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2008;26(3):399-405. PMID: 18202416.